Abstract
BackgroundDosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have